Dose Optimization of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis of 50 mg Versus 100 mg Once Daily.
Mohammed Abdulgayoom, Motaz Almahmood, Rasha Kaddoura et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of dasatinib 50 mg versus 100 mg once daily in adults with chronic-phase chronic myeloid leukemia (CP-CML). The analysis included 10 reports, with two directly comparing the doses. Results indicated that 12-month major molecular response was similar (RR 1.07), while 50 mg showed a lower incidence of pleural effusion (RR 0.20) and thrombocytopenia (RR 0.71).
Key findings
- 12-month major molecular response was similar between dasatinib 50 mg and 100 mg (RR 1.07).
- Complete cytogenetic response favored dasatinib 50 mg (RR 1.09).
- Dasatinib 50 mg significantly reduced pleural effusion (RR 0.20).
- Dasatinib 50 mg also reduced thrombocytopenia (RR 0.71).
Why it matters
Optimizing dasatinib dosing could enhance patient tolerability and adherence in chronic-phase chronic myeloid leukemia treatment, potentially leading to better long-term outcomes. Understanding the balance between efficacy and safety is crucial for clinicians managing this condition.